Eravacycline (TP-434) is efficacious in animal models of infection

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 5, 2015, Pages 2567-2571

  Grossman, Trudy H ^a   Murphy, Timothy M ^b,c   Slee, Andrew M ^b   Lofland, Denene ^a,d   Sutcliffe, Joyce A ^a  

^a Tetraphase Pharmaceuticals   (United States)

^b ViviSource Laboratories   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^d Touro University California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERAVACYCLINE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN; 7-FLUORO-9-PYRROLIDINOACETAMIDO-6-DEMETHYL-6-DEOXYTETRACYCLINE; ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; FEMALE; IN VITRO STUDY; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PYELONEPHRITIS; SEPTICEMIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOLOGY; STAPHYLOCOCCAL INFECTIONS; THIGH; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; FEMALE; LINEZOLID; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PYELONEPHRITIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TETRACYCLINES; THIGH; TREATMENT OUTCOME;

EID: 84931262480     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04354-14     Document Type: Article

References (16)

1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA.
2. Roberts RR, Hota B, Ahmad I, Scott RD, II, Foster SD, Abbasi F, Schabowski S, Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB, Weinstein RA. 2009. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 49:1175-1184. http://dx.doi.org/10.1086/605630.
3. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Jr, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
4. Rice L. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197:1079-1181. http://dx.doi.org/10.1086/533452.
5. Infectious Diseases Society of America. 2010. The 10 X '20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 50:1081-1083. http://dx.doi.org/10.1086/652237.
6. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. 2013. Antibacterial activity of ERV (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 57:5548-5558. http://dx.doi.org/10.1128/AAC.01288-13.
7. Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, Wilson DN, Sutcliffe JA. 2012. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 56:2559-2564. http://dx.doi.org/10.1128/AAC.06187-11.
8. Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Sutcliffe JA, Walpole SM, Horn PT. 2014. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother 58:1847-1854. http://dx.doi.org/10.1128/AAC.01614-13.
9. Horn PT, Sutcliffe JA, Walpole SM, Leighton A. 2011. Pharmacokinetics, safety and tolerability of a novel fluorocycline, TP-434, following multiple dose oral administration with and without food, abstr 603. Abstr 49th Annu Meet Infect Dis Am Annu Meeting, Boston, MA, 20 to 23 October 2011.
10. Ronn M, Dunwoody N, Sutcliffe J. 2010. Pharmacokinetics of TP-434 in mouse, rat, dog, monkey and chimpanzee, abstr F1-2163. Abstr 50th Annu Intersci Conf Antimicrob Agents Chemother, 12 to 15 September 2010.
11. Xiao X-Y, Hunt DK, Zhou J, Clark RB, Dunwoody N, Fyfe C, Grossman TH, O'Brien WJ, Plamondon L, Rönn M, Sun C, Zhang W-Y, Sutcliffe JA. 2012. Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem 55:597-605. http://dx.doi.org/10.1021/jm201465w.
12. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. 2010. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 50:133-164. http://dx.doi.org/10.1086/649554.
15. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ. 2008. Prevalence and risk factor analysis of trimethoprimsulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 47:1150-1158. http://dx.doi.org/10.1086/592250.
16. Lautenbach E. 2008. Finding the path of least antimicrobial resistance in pyelonephritis. Clin Infect Dis 47:1159-1161. http://dx.doi.org/10.1086/592251.